Literature DB >> 15657436

Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels.

Ivan Topisirovic1, Alex Kentsis, Jacqueline M Perez, Monica L Guzman, Craig T Jordan, Katherine L B Borden.   

Abstract

The eukaryotic translation initiation factor 4E (eIF4E) alters gene expression on multiple levels. In the cytoplasm, eIF4E acts in the rate-limiting step of translation initiation. In the nucleus, eIF4E facilitates nuclear export of a subset of mRNAs. Both of these functions contribute to eIF4E's ability to oncogenically transform cells. We report here that the homeodomain protein, HOXA9, is a positive regulator of eIF4E. HOXA9 stimulates eIF4E-dependent export of cyclin D1 and ornithine decarboxylase (ODC) mRNAs in the nucleus, as well as increases the translation efficiency of ODC mRNA in the cytoplasm. These activities depend on direct interactions of HOXA9 with eIF4E and are independent of the role of HOXA9 in transcription. At the biochemical level, HOXA9 mediates these effects by competing with factors that repress eIF4E function, in particular the proline-rich homeodomain PRH/Hex. This competitive mechanism of eIF4E regulation is disrupted in a subset of leukemias, where HOXA9 displaces PRH from eIF4E, thereby contributing to eIF4E's dysregulation. In regard to these results and our previous finding that approximately 200 homeodomain proteins contain eIF4E binding sites, we propose that homeodomain modulation of eIF4E activity is a novel means through which this family of proteins implements their effects on growth and development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15657436      PMCID: PMC544005          DOI: 10.1128/MCB.25.3.1100-1112.2005

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  35 in total

1.  Coupled transcription and translation within nuclei of mammalian cells.

Authors:  F J Iborra; D A Jackson; P R Cook
Journal:  Science       Date:  2001-06-21       Impact factor: 47.728

2.  The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells.

Authors:  C T Jordan; D Upchurch; S J Szilvassy; M L Guzman; D S Howard; A L Pettigrew; T Meyerrose; R Rossi; B Grimes; D A Rizzieri; S M Luger; G L Phillips
Journal:  Leukemia       Date:  2000-10       Impact factor: 11.528

3.  The promyelocytic leukemia protein PML interacts with the proline-rich homeodomain protein PRH: a RING may link hematopoiesis and growth control.

Authors:  Z Topcu; D L Mack; R A Hromas; K L Borden
Journal:  Oncogene       Date:  1999-11-25       Impact factor: 9.867

4.  The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E.

Authors:  A Kentsis; E C Dwyer; J M Perez; M Sharma; A Chen; Z Q Pan; K L Borden
Journal:  J Mol Biol       Date:  2001-09-28       Impact factor: 5.469

5.  PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA.

Authors:  N Cohen; M Sharma; A Kentsis; J M Perez; S Strudwick; K L Borden
Journal:  EMBO J       Date:  2001-08-15       Impact factor: 11.598

6.  Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia.

Authors:  U Thorsteinsdottir; E Kroon; L Jerome; F Blasi; G Sauvageau
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

7.  Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias.

Authors:  H J Lawrence; S Rozenfeld; C Cruz; K Matsukuma; A Kwong; L Kömüves; A M Buchberg; C Largman
Journal:  Leukemia       Date:  1999-12       Impact factor: 11.528

Review 8.  The emerging roles of translation factor eIF4E in the nucleus.

Authors:  Stephen Strudwick; Katherine L B Borden
Journal:  Differentiation       Date:  2002-03       Impact factor: 3.880

9.  The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA.

Authors:  H K Lai; K L Borden
Journal:  Oncogene       Date:  2000-03-23       Impact factor: 9.867

Review 10.  Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies.

Authors:  Katherine L B Borden
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

View more
  34 in total

1.  Regulation of p53 localization and activity by Ubc13.

Authors:  Aaron Laine; Ivan Topisirovic; Dayong Zhai; John C Reed; Katherine L B Borden; Ze'ev Ronai
Journal:  Mol Cell Biol       Date:  2006-09-25       Impact factor: 4.272

2.  Homeobox Gene Deregulation: Impact on the Hallmarks of Cancer.

Authors:  Dhwani Haria; Honami Naora
Journal:  Cancer Hallm       Date:  2013-09-01

3.  Structural characterization of the Z RING-eIF4E complex reveals a distinct mode of control for eIF4E.

Authors:  Laurent Volpon; Michael J Osborne; Althea A Capul; Juan C de la Torre; Katherine L B Borden
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-08       Impact factor: 11.205

Review 4.  Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

Authors:  Katherine L B Borden; Biljana Culjkovic-Kraljacic
Journal:  Leuk Lymphoma       Date:  2010-10

5.  Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.

Authors:  Bon Q Trinh; Song Yi Ko; Nicolas Barengo; Shiaw-Yih Lin; Honami Naora
Journal:  Cancer Res       Date:  2012-12-07       Impact factor: 12.701

6.  Phosphorylation of HOX11/TLX1 on Threonine-247 during mitosis modulates expression of cyclin B1.

Authors:  Edwin Chen; Xiaoyong Huang; Yanzhen Zheng; You-Jun Li; Alden Chesney; Yaacov Ben-David; Eric Yang; Margaret R Hough
Journal:  Mol Cancer       Date:  2010-09-16       Impact factor: 27.401

7.  HOXA9 modulates its oncogenic partner Meis1 to influence normal hematopoiesis.

Authors:  Yu-Long Hu; Steve Fong; Christina Ferrell; Corey Largman; Wei-Fang Shen
Journal:  Mol Cell Biol       Date:  2009-07-20       Impact factor: 4.272

8.  HOX proteins and leukemia.

Authors:  Kajal V Sitwala; Monisha N Dandekar; Jay L Hess
Journal:  Int J Clin Exp Pathol       Date:  2008-03-30

9.  Breaking through an epigenetic wall: re-activation of Oct4 by KRAB-containing designer zinc finger transcription factors.

Authors:  Karla Juárez-Moreno; Rafaela Erices; Adriana S Beltran; Sabine Stolzenburg; Mauricio Cuello-Fredes; Gareth I Owen; Haili Qian; Pilar Blancafort
Journal:  Epigenetics       Date:  2013-01-11       Impact factor: 4.528

10.  Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer.

Authors:  Biljana Culjkovic; Katherine L Borden
Journal:  J Oncol       Date:  2009-12-13       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.